Tag: diverticulitis disease market growth

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Diverticulitis Disease Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market encompassing diverticulitis treatments has experienced robust expansion lately, with projections indicating a substantial increase from $2.02 billion in 2025 to $2.21 billion in 2026, reflecting a compound annual growth rate of 9.0%. This prior period’s upward trajectory is linked to factors such as an expanding elderly demographic, dietary patterns characterized by insufficient fiber intake, challenges in achieving early disease detection, prevalent hospital-focused therapeutic approaches, and an increasing incidence of digestive system ailments.

The market for diverticulitis treatments is poised for substantial expansion over the upcoming years, projecting an increase to $3.22 billion by 2030, with a compound annual growth rate (CAGR) of 9.9%. This anticipated growth is fueled by several key factors, including heightened public awareness regarding digestive health and preventative measures, enhanced accessibility to advanced imaging technologies, a broader adoption of outpatient care settings, a decrease in invasive surgical procedures, and an increased emphasis on lifestyle adjustments. During this forecast period, significant trends are expected to shape the market, such as a rise in the diagnosis of less complex diverticulitis cases, a growing inclination towards non-surgical and outpatient management strategies, the expanded application of imaging for diagnosis, the increased utilization of antibiotics and supportive care, and greater consumer knowledge about managing the condition through diet and lifestyle.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

#Diverticulitis Disease Market Growth Factors: Which Forces Are Supporting Market Expansion?

The escalating incidence of smoking addiction is poised to stimulate expansion within the diverticulitis disease market. This addiction signifies a compulsive reliance on nicotine products, encompassing cigarettes, e-cigarettes, and other tobacco items. Factors contributing to this surge include robust marketing efforts, greater societal acceptance, stress as a trigger, and the wider availability of vaping devices. The diverticulitis treatment sector benefits from this trend as smoking impairs blood circulation to the colon, heightening the risk and severity of diverticular conditions, consequently increasing the necessity for diagnosis and medical management. For example, data from the European Respiratory Society (ERS) in October 2024 indicated a substantial uptick in smoking among young individuals, with 40.1% of those surveyed in 2024 reporting smoking habits, a notable increase from the 22.5% recorded in 2022. Consequently, the growing prevalence of smoking addiction is anticipated to be a key driver for the diverticulitis disease market’s growth.

## Diverticulitis Disease Market Driver: Increasing Prevalence Of Diabetes Fuels Growth In The Market

The expanding occurrence of diabetes is projected to be a significant catalyst for the diverticulitis disease market’s advancement. Diabetes is a long-term metabolic condition marked by elevated blood sugar levels, stemming from insufficient insulin production or its ineffective use. This rising tide of diabetes is largely attributed to dietary habits dominated by processed foods, inactive lifestyles, increasing obesity rates, and an aging global population. The diverticulitis disease market aligns with this trend by offering solutions for diabetes-related complications, as elevated blood glucose levels can compromise blood vessels and make the colon more vulnerable to infections and inflammation, thereby boosting the need for diagnostic tools and treatments. Illustrating this, in June 2024, the National Health Service (NHS England) reported that the number of diagnosed pre-diabetes cases climbed to 3,615,330 in 2023, an 18% jump from the 3,065,825 cases in 2022, with a particularly sharp rise of nearly 25% in individuals under 40, increasing from 173,166 in 2022 to 216,440 in 2023. Therefore, the escalating prevalence of diabetes is fueling the expansion of the diverticulitis disease market.

Diverticulitis Disease Market Segmentation And Category Breakdown

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (Ct) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive Care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (Iv) Fluids

4) By End-User: Specialty Centers, Hospitals, Research Centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Diverticulitis Disease Market Industry Trends: What Changes Are Reshaping Demand?

In the diverticulitis disease market, leading pharmaceutical firms are actively pursuing novel therapeutic agents and securing regulatory endorsements to solidify their market presence. This focus on drug discovery promises more efficacious interventions for diverticulitis, thereby mitigating complications and enhancing patient well-being. A notable advancement occurred in April 2023 when Seres’ innovative microbiota-based therapy, intended for recurrent intestinal infections, received approval from the U.S. Food and Drug Administration. This orally administered treatment, Vowst, is formulated to combat recurrent gut infections and prevent the relapse of Clostridioides difficile (C. diff.) in adult individuals 18 years and older. Its approval stemmed from a clinical investigation involving 346 participants suffering from recurrent CDI, which demonstrated a substantially reduced likelihood of infection recurrence among those administered Vowst compared to a placebo group. The drug’s efficacy is attributed to its composition of Firmicutes spores, recognized for their role in fostering a robust gut microbiome capable of impeding C. diff. colonization.

Diverticulitis Disease Market Competitive Analysis Of Major Industry Participants

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Access The Complete Diverticulitis Disease Market Report:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Diverticulitis Disease Market Regional Analysis And Leading Geography

North Americawas the largest region in the diverticulitis disease market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the diverticulitis disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Diverticulitis Disease Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market encompassing diverticulitis treatments has experienced robust expansion lately, with projections indicating a substantial increase from $2.02 billion in 2025 to $2.21 billion in 2026, reflecting a compound annual growth rate of 9.0%. This prior period’s upward trajectory is linked to factors such as an expanding elderly demographic, dietary patterns characterized by insufficient fiber intake, challenges in achieving early disease detection, prevalent hospital-focused therapeutic approaches, and an increasing incidence of digestive system ailments.

The market for diverticulitis treatments is poised for substantial expansion over the upcoming years, projecting an increase to $3.22 billion by 2030, with a compound annual growth rate (CAGR) of 9.9%. This anticipated growth is fueled by several key factors, including heightened public awareness regarding digestive health and preventative measures, enhanced accessibility to advanced imaging technologies, a broader adoption of outpatient care settings, a decrease in invasive surgical procedures, and an increased emphasis on lifestyle adjustments. During this forecast period, significant trends are expected to shape the market, such as a rise in the diagnosis of less complex diverticulitis cases, a growing inclination towards non-surgical and outpatient management strategies, the expanded application of imaging for diagnosis, the increased utilization of antibiotics and supportive care, and greater consumer knowledge about managing the condition through diet and lifestyle.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

#Diverticulitis Disease Market Growth Factors: Which Forces Are Supporting Market Expansion?

The escalating incidence of smoking addiction is poised to stimulate expansion within the diverticulitis disease market. This addiction signifies a compulsive reliance on nicotine products, encompassing cigarettes, e-cigarettes, and other tobacco items. Factors contributing to this surge include robust marketing efforts, greater societal acceptance, stress as a trigger, and the wider availability of vaping devices. The diverticulitis treatment sector benefits from this trend as smoking impairs blood circulation to the colon, heightening the risk and severity of diverticular conditions, consequently increasing the necessity for diagnosis and medical management. For example, data from the European Respiratory Society (ERS) in October 2024 indicated a substantial uptick in smoking among young individuals, with 40.1% of those surveyed in 2024 reporting smoking habits, a notable increase from the 22.5% recorded in 2022. Consequently, the growing prevalence of smoking addiction is anticipated to be a key driver for the diverticulitis disease market’s growth.

## Diverticulitis Disease Market Driver: Increasing Prevalence Of Diabetes Fuels Growth In The Market

The expanding occurrence of diabetes is projected to be a significant catalyst for the diverticulitis disease market’s advancement. Diabetes is a long-term metabolic condition marked by elevated blood sugar levels, stemming from insufficient insulin production or its ineffective use. This rising tide of diabetes is largely attributed to dietary habits dominated by processed foods, inactive lifestyles, increasing obesity rates, and an aging global population. The diverticulitis disease market aligns with this trend by offering solutions for diabetes-related complications, as elevated blood glucose levels can compromise blood vessels and make the colon more vulnerable to infections and inflammation, thereby boosting the need for diagnostic tools and treatments. Illustrating this, in June 2024, the National Health Service (NHS England) reported that the number of diagnosed pre-diabetes cases climbed to 3,615,330 in 2023, an 18% jump from the 3,065,825 cases in 2022, with a particularly sharp rise of nearly 25% in individuals under 40, increasing from 173,166 in 2022 to 216,440 in 2023. Therefore, the escalating prevalence of diabetes is fueling the expansion of the diverticulitis disease market.

Diverticulitis Disease Market Segmentation And Category Breakdown

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (Ct) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive Care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (Iv) Fluids

4) By End-User: Specialty Centers, Hospitals, Research Centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Diverticulitis Disease Market Industry Trends: What Changes Are Reshaping Demand?

In the diverticulitis disease market, leading pharmaceutical firms are actively pursuing novel therapeutic agents and securing regulatory endorsements to solidify their market presence. This focus on drug discovery promises more efficacious interventions for diverticulitis, thereby mitigating complications and enhancing patient well-being. A notable advancement occurred in April 2023 when Seres’ innovative microbiota-based therapy, intended for recurrent intestinal infections, received approval from the U.S. Food and Drug Administration. This orally administered treatment, Vowst, is formulated to combat recurrent gut infections and prevent the relapse of Clostridioides difficile (C. diff.) in adult individuals 18 years and older. Its approval stemmed from a clinical investigation involving 346 participants suffering from recurrent CDI, which demonstrated a substantially reduced likelihood of infection recurrence among those administered Vowst compared to a placebo group. The drug’s efficacy is attributed to its composition of Firmicutes spores, recognized for their role in fostering a robust gut microbiome capable of impeding C. diff. colonization.

Diverticulitis Disease Market Competitive Analysis Of Major Industry Participants

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Access The Complete Diverticulitis Disease Market Report:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Diverticulitis Disease Market Regional Analysis And Leading Geography

North Americawas the largest region in the diverticulitis disease market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the diverticulitis disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Diverticulitis Disease Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market encompassing diverticulitis treatments has experienced robust expansion lately, with projections indicating a substantial increase from $2.02 billion in 2025 to $2.21 billion in 2026, reflecting a compound annual growth rate of 9.0%. This prior period’s upward trajectory is linked to factors such as an expanding elderly demographic, dietary patterns characterized by insufficient fiber intake, challenges in achieving early disease detection, prevalent hospital-focused therapeutic approaches, and an increasing incidence of digestive system ailments.

The market for diverticulitis treatments is poised for substantial expansion over the upcoming years, projecting an increase to $3.22 billion by 2030, with a compound annual growth rate (CAGR) of 9.9%. This anticipated growth is fueled by several key factors, including heightened public awareness regarding digestive health and preventative measures, enhanced accessibility to advanced imaging technologies, a broader adoption of outpatient care settings, a decrease in invasive surgical procedures, and an increased emphasis on lifestyle adjustments. During this forecast period, significant trends are expected to shape the market, such as a rise in the diagnosis of less complex diverticulitis cases, a growing inclination towards non-surgical and outpatient management strategies, the expanded application of imaging for diagnosis, the increased utilization of antibiotics and supportive care, and greater consumer knowledge about managing the condition through diet and lifestyle.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

#Diverticulitis Disease Market Growth Factors: Which Forces Are Supporting Market Expansion?

The escalating incidence of smoking addiction is poised to stimulate expansion within the diverticulitis disease market. This addiction signifies a compulsive reliance on nicotine products, encompassing cigarettes, e-cigarettes, and other tobacco items. Factors contributing to this surge include robust marketing efforts, greater societal acceptance, stress as a trigger, and the wider availability of vaping devices. The diverticulitis treatment sector benefits from this trend as smoking impairs blood circulation to the colon, heightening the risk and severity of diverticular conditions, consequently increasing the necessity for diagnosis and medical management. For example, data from the European Respiratory Society (ERS) in October 2024 indicated a substantial uptick in smoking among young individuals, with 40.1% of those surveyed in 2024 reporting smoking habits, a notable increase from the 22.5% recorded in 2022. Consequently, the growing prevalence of smoking addiction is anticipated to be a key driver for the diverticulitis disease market’s growth.

## Diverticulitis Disease Market Driver: Increasing Prevalence Of Diabetes Fuels Growth In The Market

The expanding occurrence of diabetes is projected to be a significant catalyst for the diverticulitis disease market’s advancement. Diabetes is a long-term metabolic condition marked by elevated blood sugar levels, stemming from insufficient insulin production or its ineffective use. This rising tide of diabetes is largely attributed to dietary habits dominated by processed foods, inactive lifestyles, increasing obesity rates, and an aging global population. The diverticulitis disease market aligns with this trend by offering solutions for diabetes-related complications, as elevated blood glucose levels can compromise blood vessels and make the colon more vulnerable to infections and inflammation, thereby boosting the need for diagnostic tools and treatments. Illustrating this, in June 2024, the National Health Service (NHS England) reported that the number of diagnosed pre-diabetes cases climbed to 3,615,330 in 2023, an 18% jump from the 3,065,825 cases in 2022, with a particularly sharp rise of nearly 25% in individuals under 40, increasing from 173,166 in 2022 to 216,440 in 2023. Therefore, the escalating prevalence of diabetes is fueling the expansion of the diverticulitis disease market.

Diverticulitis Disease Market Segmentation And Category Breakdown

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (Ct) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive Care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (Iv) Fluids

4) By End-User: Specialty Centers, Hospitals, Research Centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Diverticulitis Disease Market Industry Trends: What Changes Are Reshaping Demand?

In the diverticulitis disease market, leading pharmaceutical firms are actively pursuing novel therapeutic agents and securing regulatory endorsements to solidify their market presence. This focus on drug discovery promises more efficacious interventions for diverticulitis, thereby mitigating complications and enhancing patient well-being. A notable advancement occurred in April 2023 when Seres’ innovative microbiota-based therapy, intended for recurrent intestinal infections, received approval from the U.S. Food and Drug Administration. This orally administered treatment, Vowst, is formulated to combat recurrent gut infections and prevent the relapse of Clostridioides difficile (C. diff.) in adult individuals 18 years and older. Its approval stemmed from a clinical investigation involving 346 participants suffering from recurrent CDI, which demonstrated a substantially reduced likelihood of infection recurrence among those administered Vowst compared to a placebo group. The drug’s efficacy is attributed to its composition of Firmicutes spores, recognized for their role in fostering a robust gut microbiome capable of impeding C. diff. colonization.

Diverticulitis Disease Market Competitive Analysis Of Major Industry Participants

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Access The Complete Diverticulitis Disease Market Report:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Diverticulitis Disease Market Regional Analysis And Leading Geography

North Americawas the largest region in the diverticulitis disease market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the diverticulitis disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Diverticulitis Disease Market By 2030 Based On Its 2026 Value?

The diverticulitis disease market size has seen significant expansion over recent years. It is forecast to rise from $2.02 billion in 2025 to $2.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. This historical growth can be ascribed to factors including an aging population, low fiber dietary habits, limited early diagnosis, hospital-centric treatment models, and a rising prevalence of gastrointestinal disorders.

The diverticulitis disease market is projected to experience substantial expansion in the coming years, forecast to reach $3.22 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. This growth over the forecast period is attributable to factors such as increased awareness of preventive digestive health, enhanced access to imaging, the expansion of outpatient care, a decrease in surgical intervention rates, and a greater emphasis on lifestyle adjustments. Key trends expected during this period involve a rise in the diagnosis of uncomplicated diverticulitis, a growing inclination towards conservative and outpatient management strategies, increased adoption of imaging-based diagnostics, the broadening of antibiotic and supportive care treatments, and heightened awareness regarding dietary and lifestyle management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

What Market Drivers Are Helping Shape The Diverticulitis Disease Market Expansion?

The increasing prevalence of smoking addiction is projected to drive the expansion of the diverticulitis disease market in the future. Smoking addiction describes a compulsory dependency on nicotine products such as cigarettes, vapes, and various other tobacco items. This rise in smoking addiction is largely due to aggressive promotional efforts, greater societal acceptance, stress-induced triggers, and the expanding availability of e-cigarettes and vaping devices. Diverticulitis management aligns with this pattern, given that smoking diminishes blood flow to the colon and exacerbates the risk and seriousness of diverticular disease, thereby increasing the demand for diagnostic and therapeutic solutions. For instance, in October 2024, according to the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, a study covering smoking trends among young people revealed a significant rise in smoking rates, with 22.5% of respondents smoking in 2022 compared to 40.1% in 2024. Therefore, the growing incidence of smoking addiction will stimulate the growth of the diverticulitis disease market.

How Is The Diverticulitis Disease Market Examined Through Segment Analysis?

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (Ct) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive Care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (Iv) Fluids

4) By End-User: Specialty Centers, Hospitals, Research Centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Which Trends Are Influencing The Direction Of The Diverticulitis Disease Market?

Leading companies operating in the diverticulitis disease market are engaged in developing innovative drugs and securing their approval to sustain their market position. Such drug development has the potential to lead to the creation of more effective treatments for diverticulitis, thereby reducing the risk of complications and improving patient outcomes. For instance, in April 2023, the United States Food and Drug Administration, a US-based federal organization, approved Seres’ microbiota drug for recurrent gut infections. This specific drug is formulated to treat recurring gut infections and to prevent the recurrence of Clostridioides difficile (C. diff.) infections in adults aged 18 and over. The endorsement of Vowst was established on a clinical trial that included 346 patients with recurrent CDI. The trial’s findings indicated that patients who received Vowst were considerably less prone to experiencing a recurrence of the infection than those who were given a placebo. The medication is consumed orally and is rooted in microbiota comprising Firmicutes spores, which are known for their contribution to a healthy microbiome capable of resisting C. diff. colonization.

Which Companies Form The Competitive Landscape Of The Diverticulitis Disease Market?

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Access The Complete Diverticulitis Disease Market Report:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Which Region Contributes The Most To The Diverticulitis Disease Market?

North America was the largest region in the diverticulitis disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diverticulitis disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Diverticulitis Disease Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12990&type=smp

Browse Through More Reports Similar to the Global Diverticulitis Disease Market 2026, By The Business Research Company

Intestinal Pseudo Obstruction Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/intestinal-pseudo-obstruction-treatment-global-market-report

Intestinal Pseudo Obstruction Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/intestinal-pseudo-obstruction-treatment-global-market-report

Ulcerative Colitis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Diverticulitis Disease Market Expected To Change From 2026 To 2030?

The diverticulitis disease market has experienced substantial expansion in recent years. It is anticipated to grow from $2.02 billion in 2025 to $2.21 billion in 2026, at a compound annual growth rate (CAGR) of 9.0%. The growth observed in the past can be ascribed to an expanding aging population, dietary patterns low in fiber, inadequate early diagnosis, treatment models centered in hospitals, and an increasing occurrence of gastrointestinal disorders.

The diverticulitis disease market is projected to experience robust expansion in the coming years, reaching $3.22 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.9%. This anticipated growth during the forecast period is primarily due to increased awareness of preventive digestive health, enhanced access to imaging, the expansion of outpatient care services, a decrease in surgical intervention rates, and a greater emphasis on lifestyle modifications. Key trends anticipated for this period involve a rise in the diagnosis of uncomplicated diverticulitis cases, an increasing preference for conservative and outpatient management strategies, a growing adoption of imaging-based diagnostic methods, the broadening of antibiotic and supportive care treatments, and heightened awareness regarding dietary and lifestyle management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

What Key Factors Are Affecting The Diverticulitis Disease Market Demand?

The increasing incidence of smoking dependence is projected to fuel the expansion of the diverticulitis disease market in the future. This addiction describes a strong reliance on products containing nicotine, including cigarettes, vaping devices, and other tobacco products. The rise in smoking addiction is attributed to aggressive promotional efforts, increased social acceptance, stressors, and the wider availability of electronic cigarettes and vaping devices. This trend is further supported by diverticulitis treatment, as smoking impairs blood flow to the colon, heightening the likelihood and intensity of diverticular disease, consequently boosting the demand for diagnostic and treatment solutions. For example, an October 2024 study by the European Respiratory Society (ERS), a non-profit organization based in Switzerland, on smoking trends among younger populations, demonstrated a notable increase in smoking prevalence, with 22.5% of individuals reporting smoking in 2022, rising to 40.1% in 2024. Consequently, the growing prevalence of smoking addiction will stimulate the expansion of the diverticulitis disease market.

How Is Segmentation Applied In The Diverticulitis Disease Market Segment Analysis?

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (Ct) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive Care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (Iv) Fluids

4) By End-User: Specialty Centers, Hospitals, Research Centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

What Trends Are Influencing Changes In The Diverticulitis Disease Market?

Leading companies in the diverticulitis disease market are developing and seeking approval for innovative drugs to maintain their competitive standing. Pharmaceutical development can result in more effective treatments for diverticulitis, thereby lowering the risk of complications and enhancing patient outcomes. For example, in April 2023, the United States Food and Drug Administration, a US-based federal organization, granted approval for Seres’ microbiota drug intended for recurrent gut infections. This medication is designed to treat repeated gut infections and prevent the re-occurrence of Clostridioides difficile (C. diff.) infections in adults aged 18 and over. The approval of Vowst stemmed from a clinical trial that included 346 patients experiencing recurrent CDI. The study revealed that patients treated with Vowst were significantly less prone to a recurrence of the infection than those who received a placebo. The drug is administered orally and utilizes microbiota containing Firmicutes spores, which are known to contribute to a robust microbiome capable of resisting C. diff. colonization.

Who Are The Companies Participating In The Diverticulitis Disease Market Environment?

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Get The Full Diverticulitis Disease Market Report:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Which Region Has The Greatest Market Share In The Diverticulitis Disease Market?

North America was the largest region in the diverticulitis disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diverticulitis disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Diverticulitis Disease Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Browse Through More Reports Similar to the Global Diverticulitis Disease Market 2026, By The Business Research Company

Ulcerative Colitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

Intestinal Pseudo Obstruction Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/intestinal-pseudo-obstruction-treatment-global-market-report

Intestinal Pseudo Obstruction Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/intestinal-pseudo-obstruction-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Diverticulitis Disease Market Expected To Change From 2026 To 2030?

The diverticulitis disease market has experienced substantial expansion in recent years. It is anticipated to grow from $2.02 billion in 2025 to $2.21 billion in 2026, at a compound annual growth rate (CAGR) of 9.0%. The growth observed in the past can be ascribed to an expanding aging population, dietary patterns low in fiber, inadequate early diagnosis, treatment models centered in hospitals, and an increasing occurrence of gastrointestinal disorders.

The diverticulitis disease market is projected to experience robust expansion in the coming years, reaching $3.22 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.9%. This anticipated growth during the forecast period is primarily due to increased awareness of preventive digestive health, enhanced access to imaging, the expansion of outpatient care services, a decrease in surgical intervention rates, and a greater emphasis on lifestyle modifications. Key trends anticipated for this period involve a rise in the diagnosis of uncomplicated diverticulitis cases, an increasing preference for conservative and outpatient management strategies, a growing adoption of imaging-based diagnostic methods, the broadening of antibiotic and supportive care treatments, and heightened awareness regarding dietary and lifestyle management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

What Key Factors Are Affecting The Diverticulitis Disease Market Demand?

The increasing incidence of smoking dependence is projected to fuel the expansion of the diverticulitis disease market in the future. This addiction describes a strong reliance on products containing nicotine, including cigarettes, vaping devices, and other tobacco products. The rise in smoking addiction is attributed to aggressive promotional efforts, increased social acceptance, stressors, and the wider availability of electronic cigarettes and vaping devices. This trend is further supported by diverticulitis treatment, as smoking impairs blood flow to the colon, heightening the likelihood and intensity of diverticular disease, consequently boosting the demand for diagnostic and treatment solutions. For example, an October 2024 study by the European Respiratory Society (ERS), a non-profit organization based in Switzerland, on smoking trends among younger populations, demonstrated a notable increase in smoking prevalence, with 22.5% of individuals reporting smoking in 2022, rising to 40.1% in 2024. Consequently, the growing prevalence of smoking addiction will stimulate the expansion of the diverticulitis disease market.

How Is Segmentation Applied In The Diverticulitis Disease Market Segment Analysis?

The diverticulitis disease market covered in this report is segmented –

1) By Type: Uncomplicated, Complicated

2) By Diagnosis: Computed Tomography (Ct) Scan, Ultrasound, Urine Test, Blood Test

3) By Treatment: Medications, Surgery, Supportive Care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (Iv) Fluids

4) By End-User: Specialty Centers, Hospitals, Research Centers

Subsegments:

1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy

2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

What Trends Are Influencing Changes In The Diverticulitis Disease Market?

Leading companies in the diverticulitis disease market are developing and seeking approval for innovative drugs to maintain their competitive standing. Pharmaceutical development can result in more effective treatments for diverticulitis, thereby lowering the risk of complications and enhancing patient outcomes. For example, in April 2023, the United States Food and Drug Administration, a US-based federal organization, granted approval for Seres’ microbiota drug intended for recurrent gut infections. This medication is designed to treat repeated gut infections and prevent the re-occurrence of Clostridioides difficile (C. diff.) infections in adults aged 18 and over. The approval of Vowst stemmed from a clinical trial that included 346 patients experiencing recurrent CDI. The study revealed that patients treated with Vowst were significantly less prone to a recurrence of the infection than those who received a placebo. The drug is administered orally and utilizes microbiota containing Firmicutes spores, which are known to contribute to a robust microbiome capable of resisting C. diff. colonization.

Who Are The Companies Participating In The Diverticulitis Disease Market Environment?

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Get The Full Diverticulitis Disease Market Report:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Which Region Has The Greatest Market Share In The Diverticulitis Disease Market?

North America was the largest region in the diverticulitis disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diverticulitis disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Diverticulitis Disease Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Browse Through More Reports Similar to the Global Diverticulitis Disease Market 2026, By The Business Research Company

Ulcerative Colitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

Intestinal Pseudo Obstruction Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/intestinal-pseudo-obstruction-treatment-global-market-report

Intestinal Pseudo Obstruction Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/intestinal-pseudo-obstruction-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model